" class="no-js "lang="en-US"> Obsidian Therapeutics Appoints Lee Giguere, J.D., as Chief Legal Officer and Corporate Secretary - Medtech Alert
Thursday, March 28, 2024

Obsidian Therapeutics Appoints Lee Giguere, J.D., as Chief Legal Officer and Corporate Secretary

Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced the appointment of Lee Giguere as Chief Legal Officer and Secretary. Lee will manage the legal function and serve as a key member of Obsidian’s executive leadership team, playing a critical role in the company’s strategic decision-making. He will provide operational leadership across a wide array of legal, governance and compliance matters.

“Lee’s broad experience in legal and corporate governance will be critical to Obsidian’s rapid growth as a company pioneering engineered TIL therapy,” commented Paul Wotton, Obsidian’s Chief Executive Officer. “The leadership he brings will strengthen our management team and together with his significant expertise in all legal and compliance matters, further positions Obsidian for success as we take our first cytoTIL15 program (OBX-115) into the clinic in 2022.”

Lee has wide-ranging experience and expertise in legal, healthcare compliance and corporate governance for public life science companies. He most recently served as general counsel and secretary at the biotechnology company Chiasma, Inc., responsible for all legal, compliance and human resource matters. Before joining Chiasma, he spent several years with Karyopharm Therapeutics Inc., an innovation-driven pharmaceutical company, as deputy general counsel, assistant secretary and Boston Scientific Corporation as senior securities and governance counsel. Lee began his legal career as an associate in the business law practice with Goodwin Procter. Lee earned his J.D. from Northeastern University School of Law and his B.S. from Northeastern University.

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more